FY2019 Earnings Forecast for Biohaven Pharmaceutical Holding Co Ltd Issued By Svb Leerink (NYSE:BHVN)

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Stock analysts at Svb Leerink increased their FY2019 earnings per share (EPS) estimates for shares of Biohaven Pharmaceutical in a research note issued to investors on Wednesday, November 13th. Svb Leerink analyst M. Goodman now forecasts that the company will post earnings per share of ($8.08) for the year, up from their previous estimate of ($8.35). Svb Leerink also issued estimates for Biohaven Pharmaceutical’s Q4 2019 earnings at ($2.28) EPS.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.47).

A number of other brokerages have also commented on BHVN. Zacks Investment Research lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. William Blair restated a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 17th. Canaccord Genuity set a $80.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, August 26th. Morgan Stanley set a $50.00 price target on Biohaven Pharmaceutical and gave the stock a “hold” rating in a research report on Friday, August 9th. Finally, ValuEngine lowered Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $71.80.

Shares of BHVN opened at $51.08 on Monday. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -8.31 and a beta of 0.34. The business’s fifty day moving average price is $45.01 and its two-hundred day moving average price is $47.68. Biohaven Pharmaceutical has a 52 week low of $29.17 and a 52 week high of $67.86.

In other news, Director Gregory Bailey purchased 5,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were purchased at an average price of $37.65 per share, with a total value of $188,250.00. Following the purchase, the director now directly owns 2,587,601 shares of the company’s stock, valued at approximately $97,423,177.65. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Elyse Stock sold 800 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $45.01, for a total value of $36,008.00. Following the completion of the sale, the insider now directly owns 800 shares in the company, valued at approximately $36,008. The disclosure for this sale can be found here. Insiders have sold a total of 28,500 shares of company stock worth $1,283,747 in the last ninety days. 23.90% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BHVN. Nuveen Asset Management LLC acquired a new stake in shares of Biohaven Pharmaceutical in the second quarter valued at about $38,799,000. Bank of New York Mellon Corp increased its position in shares of Biohaven Pharmaceutical by 236.8% in the second quarter. Bank of New York Mellon Corp now owns 545,594 shares of the company’s stock valued at $23,892,000 after acquiring an additional 383,594 shares during the last quarter. Brown Advisory Inc. increased its position in shares of Biohaven Pharmaceutical by 60.7% in the second quarter. Brown Advisory Inc. now owns 1,008,046 shares of the company’s stock valued at $44,144,000 after acquiring an additional 380,764 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Biohaven Pharmaceutical by 34.2% in the second quarter. Vanguard Group Inc. now owns 1,154,257 shares of the company’s stock valued at $50,545,000 after acquiring an additional 294,098 shares during the last quarter. Finally, Luminus Management LLC acquired a new stake in shares of Biohaven Pharmaceutical in the second quarter valued at about $12,572,000. 88.91% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Further Reading: Limitations to arbitrage trading

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.